PMID- 31739696
OWN - NLM
STAT- MEDLINE
DCOM- 20200109
LR  - 20200109
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Jan
TI  - 18(th) Annual Meeting of the Safety Pharmacology Society: drug safety assessment 
      on gastrointestinal system functions.
PG  - 19-22
LID - 10.1080/14740338.2020.1694902 [doi]
AB  - Introduction: The 18(th) Annual Meeting of the Safety Pharmacology Society 
      included a session dedicated to the assessment of drug safety on the 
      gastrointestinal (GI) system.Areas covered: GI anatomy, physiology, adverse 
      effects (AEs) of chemical and biological therapies, and approaches to mitigate 
      them.Expert opinion: GI AEs, albeit common and generally of minor intensity, may 
      prolong clinical development time and reduce patient compliance.
FAU - Cavero, Icilio
AU  - Cavero I
AD  - Independent Consultant in Safety Pharmacology, Paris, France.
FAU - Holzgrefe, Henry H
AU  - Holzgrefe HH
AUID- ORCID: 0000-0002-8165-0755
AD  - Independent Consultant in Safety Pharmacology, Reno, NV, USA.
LA  - eng
PT  - Journal Article
DEP - 20191208
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
SB  - IM
MH  - Animals
MH  - Drug Development/methods
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology
MH  - Gastrointestinal Diseases/*chemically induced
MH  - Gastrointestinal Tract/*drug effects
MH  - Humans
OTO - NOTNLM
OT  - Adverse drug reactions
OT  - ICH S7A guidelines
OT  - adverse effect mitigation
OT  - anticancer agents
OT  - drug safety
OT  - gastrointestinal system
OT  - safety pharmacology
EDAT- 2019/11/20 06:00
MHDA- 2020/01/10 06:00
CRDT- 2019/11/20 06:00
PHST- 2019/11/20 06:00 [pubmed]
PHST- 2020/01/10 06:00 [medline]
PHST- 2019/11/20 06:00 [entrez]
AID - 10.1080/14740338.2020.1694902 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2020 Jan;19(1):19-22. doi: 10.1080/14740338.2020.1694902. 
      Epub 2019 Dec 8.